ribociclib
novartis
['maintain trial', 'bcsm']
maintain trial showed ribo + exemestane or fulv showed effectiveness in pts previous treated with cdk/4/6i. most inspiring quote from dr dejan juric was that there may be differences between cdk/4/6 inhibitors and deserves more study. #asco22 #bcsm 
Metastatic Thriver, Lead Research Advocate and Publications Curator- Lobular Breast Cancer Alliance. https://t.co/Nu1hbUN17g; @LobularBCA. Tweets are my own.